Sitagliptin reduces albuminuria in patients with type 2 diabetes

Endocrine Journal

Volumn 58, Issue 1, 2011, Pages 69-73

  Hattori, Sachiko ^a  

^a Tsunemi cho Clinic   (Japan)

Author keywords

Albuminuria; DPP 4 inhibitor; eGFR

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; SITAGLIPTIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALBUMINURIA; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CREATININE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 79251604529     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-382     Document Type: Article

References (15)

1. de Valk HW (2007) DPP-4 inhibitors and combined treatment in type 2 diabetes: Re-evaluation of clinical success and safety. Rev Diabet Stud 4:126-133.
2. Chia CW, Egan JM (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93:3703-3716.
3. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343.
4. Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151:3049-3060.
5. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group (2010) Severe hypo glycemia and risks of vascular events and death. N Engl J Med 363:1410-1418.
6. Horváth EM, Benko R, Kiss L, Murányi M, Pék T, Fekete K, Bárány T, Somlai A, Csordás A, Szabo C (2009) Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase, and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 52:952-961.
7. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S (2010) Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation endproduct (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 391:1405-1408.
8. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP (2009) Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30:1735-1741.
9. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90.
10. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M (2011) Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea, and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 13:81-88.
11. Gnudi L, Goldsmith D (2010) Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep 2:pii: 18.
12. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008) (R)-8-(3-aminopiperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182.
13. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343.
14. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F (2010) Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010:592760.
15. Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators (2008) Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74:364-369.